- CEO
- Xiang Miao
- Full Time Employees
- 1,957
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Kangtai Group Building Shenzhen GD China 518057
- IPO Date
- Feb 7, 2017
- Business
- Shenzhen Kangtai Biological Products Co., Ltd. (300601.SZ) engages primarily in the research, development, production, and sales of human vaccines in China. The company offers a portfolio of marketed vaccines including recombinant hepatitis B vaccines in 10ug, 20ug, and 60ug doses (world's first 60-microgram formulation), 13-valent pneumococcal polysaccharide conjugate vaccines (dual-carrier), 23-valent pneumococcal polysaccharide vaccines, Haemophilus influenzae type b (HIB) conjugate vaccines, diphtheria-tetanus-acellular pertussis-Haemophilus influenzae type b combined vaccines, cell-free whitebait b-type Haemophilus influenzae combined vaccines, measles-rubella combined vaccines, SARS-CoV-2 vaccines, freeze-dried varicella vaccines, and four-dose human diploid cell rabies vaccines; its research and development pipeline encompasses rabies vaccines for human use, inactivated poliomyelitis vaccines, live attenuated varicella vaccines, and platforms for live attenuated viral vaccines, inactivated viral vaccines, recombinant protein vaccines, bacterial polysaccharide vaccines, bacterial polysaccharide conjugate vaccines, combination vaccines, viral vector vaccines, mRNA vaccines, and new adjuvant technologies. Founded in 1992 and headquartered in Shenzhen, China, the company operates five major R&D and industrial bases in Shenzhen and Beijing, with a marketing network spanning 31 provinces, autonomous regions, and municipalities in China, targeting public health needs across infant, pediatric, adult, and high-risk populations. In a key recent development, Shenzhen Kangtai formed a 50-50 joint venture with AstraZeneca in April 2025 in the Beijing Economic-Technological Development Area to research, develop, and produce innovative vaccines, with registered capital of RMB 345 million and total investment of approximately USD 400 million, marking AstraZeneca's first vaccine production hub in China and enhancing the company's global reach for Chinese and emerging markets.